Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

about

Recombinant factor VIIa addition to haemophilic blood perfused over collagen/tissue factor can sufficiently bypass the factor IXa/VIIIa defect to rescue fibrin generation.

Item

http://www.wikidata.org/entity/Q45867421

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@en

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@nl

type

Item

label

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@en

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@nl

prefLabel

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@en

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@nl

P1476

Recombinant factor VIIa additi ...... t to rescue fibrin generation.

@en

P2093

A Cuker

http://www.w3.org/2001/XMLSchema#string

K A Panckeri

http://www.w3.org/2001/XMLSchema#string

P F Fogarty

http://www.w3.org/2001/XMLSchema#string

S L Diamond

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models

Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin

The hemophilias--from royal genes to gene therapy.

P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions.

FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow

Microfluidic assay of hemophilic blood clotting: distinct deficits in platelet and fibrin deposition at low factor levels.

FVIIa as used pharmacologically is not TF dependent in hemophilia B mice

Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.

The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa.

Evaluation of a novel flow chamber system to assess clot formation in factor VIII-deficient mouse and anti-factor IXa-treated human blood.

P304

759-768

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13259

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

R Li

P577

2017-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28475272

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

Coagulation factor IX

P932

5623167

http://www.w3.org/2001/XMLSchema#string